Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biotech to Present Alzheimer's Disease Therapeutic at Keystone Symposium
News Update

Share on Stocktwits


The focus will be the Canadian company's lead monoclonal antibody candidate.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release it will present data during the poster session at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to be held June 16 to 19, 2019, in Colorado.

The topic of Chief Development Officer Dr. Johanne Kaplan's presentation will be PMN310, ProMIS' lead candidate and monoclonal antibody for Alzheimer's disease and will encompass key data showing how PMN310 selectively targets toxic forms of amyloid beta, believed to be a root case of the disease.

Along with PMN310's superior selectivity for amyloid beta toxic oligomers, the data will show that PMN310 could possibly be administered at high doses safely, with a reduced risk of brain swelling or amyloid-related imaging abnormality, and could potentially cause greater therapeutic effect than other amyloid beta-targeted antibodies. PMN310 is currently in advanced preclinical development.

"Evidence continues to mount, showing that amyloid-beta toxic oligomers, not amyloid plaque, are the key target for Alzheimer's disease therapy," Kaplan said in the release. "Our data will demonstrate the unique ability of the ProMIS discovery platform to generate antibodies that bind the toxic species of amyloid beta while preserving healthy forms of the protein."


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe